Envoya
Agent21Agent Readiness: 21/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Trust62Data Trust: 62/100. Above median. Measured by StartupHub.ai. Median 61.Developing polymer-based nanoparticles for targeted gene therapy delivery.
About
Envoya is an AI-powered biomedical technology company developing next-generation gene delivery systems. They create polymer-based nanoparticles using FDA-approved materials for safer and more effective delivery of genetic material, enabling groundbreaking treatments for various diseases. Envoya serves academic institutions and pharmaceutical companies seeking to overcome gene therapy's delivery barriers.
Listed competitors
A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Also in this space
AI-driven digital twin of embryo development for cell-based therapies.
Shares Life Sciences, Genetics
AI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.
Shares Life Sciences, Drug Delivery
Synthetic biology startup optimizing gene expression for food and biotech applications.
Shares Life Sciences, Genetics
Developing a semiconductor-based protein detector using nanopore sensing for advanced identification.
Shares Life Sciences, Biotech
Biopharmaceutical company developing targeted neutrophil nanoparticle platform for chronic diseases.
Shares Life Sciences, Biotech
Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.
Shares Life Sciences, Biotech
Key facts
At-a-glance profile data
- Website
- envoyabio.com
- Headquarters
- San Diego, United States
- Founded
- 2021
- Employees
- 10
- Total funding
- $2M (Pre-Seed)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 13 Dec 2023 | Pre-Seed | $2M | - |
Tech stack
Detected on envoyabio.com, last scanned 15 Oct 2026. Run your own scan
- CDN
- Netlify
- Email provider
- Google Workspace
Frequently asked
Is Envoya trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Envoya is 62 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Envoya raised?
Envoya has raised a total of $2M in funding. The most recent round on record is Pre-Seed.
How many employees does Envoya have?
Envoya has approximately 10 people on record.
